178 related articles for article (PubMed ID: 32120273)
1. 5-Fluorouracil-induced hyperammonaemic encephalopathy: A French national survey.
Boilève A; Thomas L; Lillo-Le Louët A; Gaboriau L; Chouchana L; Ducreux M; Malka D; Boige V; Hollebecque A; Hillaire-Buys D; Jozwiak M
Eur J Cancer; 2020 Apr; 129():32-40. PubMed ID: 32120273
[TBL] [Abstract][Full Text] [Related]
2. 5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy.
Boilève A; Wicker C; Verret B; Leroy F; Malka D; Jozwiak M; Pontoizeau C; Ottolenghi C; De Lonlay P; Ducreux M; Hollebecque A
Anticancer Drugs; 2019 Mar; 30(3):313-317. PubMed ID: 30531368
[TBL] [Abstract][Full Text] [Related]
3. Intermediate dose 5-fluorouracil-induced encephalopathy.
Kim YA; Chung HC; Choi HJ; Rha SY; Seong JS; Jeung HC
Jpn J Clin Oncol; 2006 Jan; 36(1):55-9. PubMed ID: 16436463
[TBL] [Abstract][Full Text] [Related]
4. High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy.
Yeh KH; Cheng AL
Br J Cancer; 1997; 75(3):464-5. PubMed ID: 9020500
[No Abstract] [Full Text] [Related]
5. Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia.
Nishikawa Y; Funakoshi T; Horimatsu T; Miyamoto S; Matsubara T; Yanagita M; Nakagawa S; Yonezawa A; Matsubara K; Muto M
Cancer Chemother Pharmacol; 2017 Mar; 79(3):629-633. PubMed ID: 28204913
[TBL] [Abstract][Full Text] [Related]
6. Acute encephalopathy attributed to 5-FU.
Langer CJ; Hageboutros A; Kloth DD; Roby D; Shaer AH
Pharmacotherapy; 1996; 16(2):311-3. PubMed ID: 8820478
[TBL] [Abstract][Full Text] [Related]
7. 5-FU-induced hyperammonemic encephalopathy in a case of metastatic rectal adenocarcinoid successfully rechallenged with the fluoropyrimidine analog, capecitabine.
Advani PP; Fakih MG
Anticancer Res; 2011 Jan; 31(1):335-8. PubMed ID: 21273620
[TBL] [Abstract][Full Text] [Related]
8. 5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases.
Cordier PY; Nau A; Ciccolini J; Oliver M; Mercier C; Lacarelle B; Peytel E
Cancer Chemother Pharmacol; 2011 Sep; 68(3):823-6. PubMed ID: 21553285
[TBL] [Abstract][Full Text] [Related]
9. Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: A case series and review of the literature.
Mitani S; Kadowaki S; Komori A; Sugiyama K; Narita Y; Taniguchi H; Ura T; Ando M; Sato Y; Yamaura H; Inaba Y; Ishihara M; Tanaka T; Tajika M; Muro K
Medicine (Baltimore); 2017 Jun; 96(22):e6874. PubMed ID: 28562536
[TBL] [Abstract][Full Text] [Related]
10. Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection.
Liaw CC; Wang HM; Wang CH; Yang TS; Chen JS; Chang HK; Lin YC; Liaw SJ; Yeh CT
Anticancer Drugs; 1999 Mar; 10(3):275-81. PubMed ID: 10327032
[TBL] [Abstract][Full Text] [Related]
11. [Four cases of 5-fluorouracil-related hyperammonemia in patients with large intestinal cancer and multiple liver metastases, including a case of hyperammonemia treated using hemodialysis].
Iida T; Wagatsuma K; Tani M; Sasaki H; Naganawa Y; Isshiki H; Murakami K; Satoh S; Shimizu H; Kaneto H
Nihon Shokakibyo Gakkai Zasshi; 2015 Feb; 112(2):287-96. PubMed ID: 25748155
[TBL] [Abstract][Full Text] [Related]
12. Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting.
Dealberto MJ
Int Clin Psychopharmacol; 2007 Nov; 22(6):330-7. PubMed ID: 17917551
[TBL] [Abstract][Full Text] [Related]
13. Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses.
Ozaki Y; Imamaki H; Ikeda A; Oura M; Nakagawa S; Funakoshi T; Kataoka S; Nishikawa Y; Horimatsu T; Yonezawa A; Matsubara T; Yanagita M; Muto M; Watanabe N
Cancer Chemother Pharmacol; 2020 Nov; 86(5):693-699. PubMed ID: 33011861
[TBL] [Abstract][Full Text] [Related]
14. The aggravating factors of hyperammonemia related to 5-fluorouracil infusion--a report of two cases.
Kikuta S; Asakage T; Nakao K; Sugasawa M; Kubota A
Auris Nasus Larynx; 2008 Jun; 35(2):295-9. PubMed ID: 17826933
[TBL] [Abstract][Full Text] [Related]
15. Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion.
Tipples K; Kolluri RB; Raouf S
J Oncol Pharm Pract; 2009 Dec; 15(4):237-9. PubMed ID: 19276137
[TBL] [Abstract][Full Text] [Related]
16. Fluorouracil-induced Hyperammonemia in a Patient with Colorectal Cancer.
Thomas SA; Tomeh N; Theard S
Anticancer Res; 2015 Dec; 35(12):6761-3. PubMed ID: 26637893
[TBL] [Abstract][Full Text] [Related]
17. Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.
Saif MW; Diasio RB
Cancer Chemother Pharmacol; 2016 Jul; 78(1):151-6. PubMed ID: 27278667
[TBL] [Abstract][Full Text] [Related]
18. Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
Ho YF; Lu WC; Chen RR; Cheng AL; Yeh KH
Anticancer Drugs; 2011 Mar; 22(3):290-8. PubMed ID: 21150775
[TBL] [Abstract][Full Text] [Related]
19. [A Case of Hyperammonemia Induced by Chemotherapy with 5-Fluorouracil for Metastatic Colon Cancer].
Tokuyama S; Fukunaga M; Konishi K; Honda S; Yukimoto R; Okamoto A; Saito A; Okada K; Ota H; Yokoyama S; Miki H; Kobayashi K
Gan To Kagaku Ryoho; 2018 Apr; 45(4):743-745. PubMed ID: 29650854
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.
Baker SD; Diasio RB; O'Reilly S; Lucas VS; Khor SP; Sartorius SE; Donehower RC; Grochow LB; Spector T; Hohneker JA; Rowinsky EK
J Clin Oncol; 2000 Feb; 18(4):915-26. PubMed ID: 10673535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
